Brain inflammation is a major factor in epilepsy, but the impact of specific inflammatory mediators on neuronal excitability is incompletely understood. Using models of acute and chronic seizures in C57BL/6 mice, we discovered a proconvulsant pathway involving high-mobility group box-1 (HMGB1) release from neurons and glia and its interaction with Toll-like receptor 4 (TLR4) 
Epilepsy is a disabling neurological disorder characterized by recurring, unprovoked seizures. It affects about 1% of the population of all ages and often requires lifelong medication 1 . In about 30% of affected individuals, epilepsy is refractory to pharmacological treatment 2 , and surgical removal of the epileptic focus is suitable only for a minority of them. Understanding the molecular events underlying the occurrence of seizures is necessary for devising new therapeutic approaches.
Increasing evidence supports the involvement of inflammatory and immune processes in the etiopathogenesis of seizures 3 . Inflammatory responses induced by brain-damaging events such as neurotrauma, stroke, infection, febrile seizures and status epilepticus are associated with acute symptomatic seizures and a high risk of developing epilepsy 4, 5 . Pronounced inflammatory processes have been described in epileptogenic brain tissue from drug-resistant patients with temporal lobe epilepsy (TLE) [6] [7] [8] and epilepsies associated with developmental malformations of the cortex 9, 10 . Pharmacological and genetic studies in animal models have shown that specific inflammatory mediators such as cytokines, complement factors and prostaglandins substantially contribute to seizures and that interfering with these molecules or their receptors can reduce seizure frequency and severity 11 .
We previously showed in rats and mice that the proinflammatory cytokine IL-1β is rapidly upregulated during seizures in microglia, astrocytes and endothelial cells in the epileptic focus as well as in forebrain regions recruited in epileptic activity 8, [12] [13] [14] . IL-1β exerts powerful proconvulsant actions via a signaling pathway in neurons involving its receptor IL-1R1, the IL-1R accessory protein and myeloid differentiation primary response protein (MyD88) complex and Src family kinases, leading to NMDA receptor-2B (NR2B) phosphorylation and enhanced NMDA-dependent Ca 2+ influx 12, 15, 16 .
The pathway activated by IL-1β depends on MyD88, but other surface receptors can recruit MyD88, notably TLRs, which have a key role in pathogen recognition 17 . TLRs recognize various molecules of microbial origin, called pathogen-associated molecular patterns (PAMPs), and trigger inflammation by inducing the transcription of genes encoding cytokines, including IL-1β. TLR4 in particular detects lipopolysaccharide (LPS), a major outer membrane component of Gram-negative bacteria. Given that TLR4 is expressed in the brain 18 and LPS lowers the seizure threshold in rodents 19, 20 , we sought to investigate whether TLR4 has a role in the onset and recurrence of seizures.
Increasing evidence indicates that, in the absence of pathogens, TLR signaling can be activated by molecules released by injured tissue 21 . These molecules, named damage-associated molecular patterns (DAMPs), include HMGB1, a nearly ubiquitous chromatin component that is passively released by necrotic cells, retained by Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures 4 1 4 VOLUME 16 | NUMBER 4 | APRIL 2010 nature medicine cells undergoing programmed death (apoptosis) and actively secreted by cells in profound distress 22, 23 . HMGB1 secretion does not follow the canonical endoplasmic reticulum-Golgi pathway and occurs via relocation of the nuclear protein to the cytoplasm 24 . Extracellular HMGB1 binds the receptor for advanced glycation end products 22 and several other receptors, including TLR4 25, 26 . We asked whether proconvulsive stimuli could lead to HMGB1 release and TLR4 activation, thereby contributing to seizures. Our results indicate that HMGB1 and TLR4 contribute to the generation and severity of seizures, which therefore can be reduced by TLR4 and HMGB1 antagonists. Studies in spontaneously epileptic mice and in human TLE tissue indicate that the HMGB1-TLR4 axis also contributes to seizures in chronic epilepsy.
RESULTS

Expression of HMGB1 and TLR4 in mouse models of seizures
We first investigated whether seizure activity affects the expression of HMGB1 and TLR4. We used two mouse models of focal-onset acute seizures induced by unilateral intrahippocampal injection of kainic acid (7 ng) or bicuculline (51 ng) (Supplementary Fig. 1 ). Kainic acid is an agonist of one class of glutamate receptors, whereas bicuculline is an antagonist of γ-aminobutyric acid A receptors; they trigger seizures by increasing excitatory neurotransmission and decreasing inhibitory neurotransmission, respectively. In these models, the seizure activity is similar and occurs to the same extent in the injected and contralateral side of the hippocampus. Kainic acid at low dose causes excitotoxic cell damage only to pyramidal cells in the CA3 area of the injected hippocampus 16, 27 , whereas bicuculline provokes seizures in the absence of neurodegeneration 28 . We also used an established mouse model of chronic epilepsy, where seizure activity develops within 1 week after intrahippocampal application of 200 ng kainic acid 29, 30 . This model recapitulates the major neuropathological features of human TLE (Supplementary Fig. 2 ) and, in particular, recurring spontaneous seizures that do not respond to various anticonvulsant drugs 29 .
We investigated the distribution of the immunohistochemical signal of HMGB1 in mice injected with kainic acid (Fig. 1a-d) . In control hippocampi, HMGB1 is present mostly in nuclei of the pyramidal neurons (Fig. 1a) and granule cells of the dentate gyrus (data not shown). In the strata radiatum, lacunosum-moleculare and moleculare, we observed scattered cells with nuclear staining as well as neurons with both nuclear and cytoplasmic staining; most cells were HMGB1 negative (Fig. 1a) . Between 1 and 3 h after the onset of seizures, we found a progressive increase in nuclear and perinuclear HMGB1 staining in astrocytes ( Fig. 1a-c ) in all subfields of injected ( Fig. 1d ) and contralateral hippocampi ( Supplementary Fig. 3b ).
Although we did not detect HMGB1 in cells with microglial morphology in control hippocampi, a short-lived wave of cytoplasmic expression in microglia appeared 1 h after seizure onset and was again absent after 3 h ( Fig. 1a-d ). In agreement with immunohistochemical results, we measured, by western blotting, an average 27% increase in HMGB1 abundance in kainic acid-injected hippocampi 3 h after the onset of seizures (Fig. 1e) . This increase in the whole tissue represents a substantial increase in the fraction of cells affected. The induction of HMGB1 in the hippocampus after bicucullineinduced seizures was bilateral and similar to that described for kainic acid-induced seizures ( Supplementary Figs. 3 and 4) , although the changes were less prominent. In chronic epileptic mice, the cell pattern and extent of HMGB1 expression in hippocampi (Supplementary Figs. 3 and 5) were similar to those described after acute kainic acidinduced seizures.
We did not find a parallel change in the number of neurons showing nuclear staining, cytoplasmic staining or both in any seizure model (data not shown). All changes observed in the CA1 region were similar in the CA3 region and in dentate gyrus (data not shown).
We next investigated TLR4 expression ( Fig. 1f-h and Supplementary  Figs. 4 and 5). Whereas we found no signal in control slices (Fig. 1f) , we observed substantial TLR4 expression 1 h (Fig. 1g ) and 3 h (Fig. 1h) after seizure onset in neurons within the pyramidal layers; glial fibrillary acidic protein (GFAP)-positive astrocytes also expressed TLR4 in the various hippocampal subfields including CA1 (Fig. 1g,h ), CA3 and hilus (data not shown). TLR4 was not expressed in CD11b-positive cells of microglial morphology (Fig. 1g,h ). As a positive control, we did detect TLR4 in CD11b-positive cells in the hippocampus after intraventricular LPS injection (Fig. 1i) . We observed a similar pattern of TLR4 induction in both neurons and astrocytes, but not in microglia, in chronic epileptic mice ( Supplementary Fig. 5 ). In bicuculline-injected mice, TLR4 staining increased bilaterally in neurons, but not in astrocytes, 1.5 h after the onset of seizures, when epileptic activity had just abated ( Supplementary Fig. 4 ). These differences from the kainic acid model may be due to the lack of cell loss, the shorter duration of seizures (90 min bicuculline versus 120 min kainic acid) or both.
Expression of HMGB1 and TLR4 in human epileptogenic tissue
Having characterized a specific pattern of HMGB1 and TRL4 expression in the hippocampi of chronic epileptic mice, we looked for a similar pattern in hippocampal specimens obtained at surgery in subjects with drug-resistant TLE with hippocampal sclerosis (TLE-HS) (Fig. 2) . In autoptic control tissue, we detected HMGB1 signal in nuclei of cells identified a posteriori as neurons and astrocytes, as well as in neuronal cytoplasm (Fig. 2a) . In TLE-HS, cytoplasmic HMGB1 staining was substantially increased in GFAP-positive astrocytes as well as in human leukocyte antigen DR (HLA-DR)-positive processes (Fig. 2a-c) .
TLR4 was undetectable in autoptic control hippocampi, whereas it was clearly detectable in pyramidal neurons and GFAP-positive astrocytes in TLE-HS specimens (Fig. 2d) . HLA-DR-positive microglia-like cells did not show TLR4 staining (Fig. 2e) , whereas HLA-DR-positive cells in multiple sclerosis specimens did stain for TLR4 (Fig. 2f) . We found similar patterns in the CA3 and hilus of the dentate gyrus (data not shown). HMGB1 and TLR4 staining in surgical hippocampal specimens from subjects with focal epileptogenic lesions not involving the hippocampus proper was similar to that in autoptic control tissue (data not shown).
HMGB1 promotes seizures in a TLR4-dependent way HMGB1 and TLR4 form a ligand-receptor pair. To examine whether TLR4 activation by HMGB1 contributes to ictogenesis, we used pharmacological and genetic approaches. First, we increased extracellular HMGB1 amounts in C57BL/6 mice by intrahippocampal injection of recombinant HMGB1 15 min before kainic acid application (Fig. 3a) . HMGB1 addition (5.5 and 9.5 µg per mouse) increased the frequency of kainic acid-induced seizures by about 2.5-fold (representative electroencephalogram (EEG) tracings in Supplementary  Fig. 1a-d ) and the total time spent in seizures. The time of onset of the first seizure was markedly reduced by 9.5 µg HMGB1. An HMGB1 dose of 3.2 µg per mouse was ineffective. We next investigated whether HMGB1 signals through TLR4 by using C3H/HeJ mice, which have a spontaneous mutation in the Toll/IL-1 receptor domain of TLR4 (Tlr4 Lps-d ), leading to functional inactivation of the receptor 31 . HMGB1 (5.5 µg per mouse) had no effect on kainic acid-induced seizures when injected into C3H/HeJ mice but was proconvulsant in their wild-type C3H/HeouJ counterparts, increasing the time spent in seizures by about twofold (Fig. 3b and Supplementary  Fig. 1f-i) . C3H/HeJ mice also had a reduced intrinsic susceptibility to seizures, as shown by a delay in kainic acid-induced seizure onset and a substantial reduction in seizure frequency and total duration (Fig. 3b) .
Overstimulated neurons release HMGB1
A high local concentration of glutamate, resulting from hyperexcitation of the neuronal network, is thought to have a key role in the initiation and spread of seizures. We thus hypothesized that overstimulation of glutamate receptors might induce neurons to release HMGB1.
We exposed mixed primary cocultures of neurons and glia to 0.25 mM glutamate for 2 h then fixed and immunostained the cells (Supplementary Fig. 6 ). HMGB1 was located only in the nuclei of unchallenged neurons and glial cells; after glutamate exposure, HMGB1 signal was still present only in the nuclei of glial cells, but in neurons it was located in both the nucleus and the cytoplasm (neuNpositive cells, Supplementary Fig. 6a ). We confirmed these results in primary cortical neurons infected with a lentivirus expressing an HMGB1-GFP fusion protein. Unchallenged neurons contained HMGB1-GFP only in the nucleus, whereas neurons exposed to 0.25 mM glutamate had a large amount of HMGB1-GFP throughout the cell bodies and processes (Supplementary Fig. 6b) .
Neurons overstimulated by glutamate eventually undergo excitotoxic death. Cortical neurons exposed in vitro to 0.25 mM glutamic acid started to die after about 2 h and were almost completely dead after 24 h, as judged morphologically (Supplementary Fig. 6c ) and by the release of lactate dehydrogenase (Supplementary Fig. 6d) . Notably, HMGB1 was also released into the medium (Supplementary Fig. 6d ). We showed previously that HMGB1 retention upon apoptosis depends on caspase-3 activation 32 ; caspase-3 was not activated by glutamate exposure, nor was DNA fragmented (ref. 33 and data not shown).
HMGB1 and TLR4 antagonists reduce acute and chronic seizures
Overall, our findings predict that pharmacological blockade of the HMGB1-TLR4 axis should reduce the frequency and duration of seizures. We then interfered with the activity of endogenous HMGB1 by injecting BoxA, a fragment of HMGB1 with antagonistic activity [34] [35] [36] . BoxA injection (7.5 µg per mouse) delayed the onset of seizures (Fig. 4a) reduced the frequency and duration of kainic acid-induced seizures (Fig. 4b,c) ; a dose of 0.8 µg was ineffective. We then tested two TLR4 antagonists, Rhodobacter sphaeroides LPS (Lps-Rs) 37 and cyanobacterial LPS (Cyp) 38 . Lps-Rs had anticonvulsant effects already at 2 µg per mouse (Fig. 4a-c) . Both antagonists at 5 µg per mouse substantially ameliorated all parameters of kainic acid-induced seizures (Fig. 4a-c) .
BoxA and Lps-Rs were also highly effective in the bicuculline model; mice experienced substantially fewer seizures, spent less time in seizures and seizure onset was delayed (Fig. 4d-f) .
Finally, we targeted the HMGB1-TLR4 axis in the model of chronic spontaneous seizures (Fig. 5) . We recorded EEG activity in C57BL/6 mice with a stable baseline of spontaneous seizures before and after injection of BoxA (7.5 µg per mouse) or Lps-Rs (5 µg per mouse). Each antagonist lowered the number and frequency of spontaneous seizures up to ~75% for about 2 h after administration (Fig. 5c) . Fig. 2 contain details) . The first EEG recording period (0-2 h) was used to assess the baseline of spontaneous seizure activity before drug injection (BoxA, 7.5 µg per mouse or Lps-Rs, 5 µg per mouse). EEG activity was then measured continuously after drug injection, and data were binned in 2-h periods. BoxA and Lps-Rs were injected into the same mice, 5 d apart; mice were also injected with PBS 24 h after the last drug administration. Fig. 2 ). **P < 0.01 versus baseline by repeated measures ANOVA followed by Dunnett's test. Fig. 2) . ND, not detectable. NR2B as a molecular target of HMGB1-TLR4 signaling IL-1β, upon binding IL-1R1, exerts its proconvulsant effects by activating NR2B-containing NMDA receptors 12, 15, 16 . Accordingly, ifenprodil, a selective blocker of NR2B-containing NMDA receptors 39 , abrogates the proconvulsant activity of IL-1β 16 . As both TLR4 and IL-1R1 signaling depend on the MyD88 adapter protein, we investigated whether HMGB1 acts like IL-1β. Ifenprodil injected together with kainic acid and HMGB1 eliminated the proconvulsant effect of HMGB1, returning all seizure parameters to the values observed in mice injected with kainic acid alone (Fig. 6a) . As shown for IL-1β 15, 16 , HMGB1 increased NR2B phosphorylation by 1.7-fold, as assessed by western blotting of hippocampal homogenates, comparable to the effect of kainic acid alone (not shown). However, ifenprodil had no effect on seizures induced by kainic acid alone. We administered ifenprodil either intraperitoneally (40 mg per kg body weight 40 ), intracerebroventricularly (80 µmol per mouse 41 ) or intrahippocampally (50 pmol per mouse 42 ) before injecting kainic acid, but none of these experimental regimens affected seizure parameters (data not shown). We thus hypothesized that ifenprodil might affect ictogenesis only in the context of an inflammatory milieu, as mimicked by exogenous application of HMGB1 and as typical of the hippocampus of chronically epileptic mice (Supplementary Fig. 2) . Indeed, ifenprodil administered intraperitoneally (40 mg per kg body weight) reduced by 60-100% the number and duration of spontaneous seizures in each of six chronically epileptic mice (Fig. 6b-h) .
DISCUSSION
This study identifies the involvement of HMGB1 and TLR4 in the generation and recurrence of seizures and describes previously unrecognized inhibitors of ictal activity. We used two models of acute seizures (kainic acid-induced and bicuculline-induced) and one chronic model of spontaneous recurrent seizures. We also show that the histopathological patterns of HMGB1 and TLR4 expression in the mouse model of spontaneous recurrent seizures and in hippocampal specimens from subjects with TLE are very similar.
The experimental evidence for the involvement of the HMGB1-TLR4 axis in seizures is based on the anticonvulsant activity of TLR4 inhibitors and BoxA, a competitor of endogenous HMGB1. Moreover, mutant mice with impaired TLR4 signaling do not respond to HMGB1 and are spontaneously resistant to kainic acid-induced seizures.
TLR4 activation by LPS, mimicking bacterial infection, decreases seizure threshold in adult and immature mice and rats 19, 20 and is associated with a chronic increase in hippocampal neuronal network excitability 20 . In these studies, the effects of LPS developed over a time frame of several hours to weeks and were attributed to the transcriptional activation of inflammatory or neuronal plasticity genes 43 in response to PAMPs. A recent report showed that LPS may cause epileptiform activity in rats, with a rapid time of onset 44 . In our studies, TLR4-mediated effects in acute seizures occur in less than 10 min and are initiated by HMGB1, a DAMP released by damaged or highly stressed cells, which acts as the TLR4 ligand. Although seizure susceptibility can be increased by infective agents 45 , epileptic activity usually occurs in sterile conditions where PAMPs are not present. DAMPs, and HMGB1 in particular, are therefore likely to have a key role in seizure precipitation and recurrence. HMGB1 might also contribute to the known association between brain injury and epilepsy 46 .
The effects of HMGB1 and IL-1β seem very similar, especially because both are blocked by ifenprodil (as shown here and in and refs. 15,16), a selective antagonist of NR2B-containing NMDA receptors 47 . Whereas the HMGB1-TLR4 axis contributes to both acute and chronic seizures, ifenprodil has no effect on acute seizures but substantially reduces the frequency and duration of spontaneous seizures in chronic epileptic mice. We suggest that NR2B-containing NMDA receptors are not involved in the ictogenic activity of the HMGB1-TLR4 axis unless a preexisting or persistent inflammatory milieu is present, as occurs in chronic epileptic tissue [6] [7] [8] [9] [10] or as mimicked by preapplication of HMGB1.
Although it is clear that HMGB1 and TLR4 participate in the chain of events leading to the precipitation and recurrence of seizures, as indicated by our genetic and pharmacological studies, the source of HMGB1 is less clear and seems to change over time. Given that HMGB1 is present in the nuclei of principal neurons before convulsant challenge, we hypothesize that HMGB1 is released by pyramidal and granule neurons after or concomitantly with the release of glutamate (Supplementary Fig. 7) . Indeed, our in vitro data clearly show that neurons undergoing excitotoxic death release HMGB1, suggesting that CA3 pyramidal cells killed by kainic acid can be a source of HMGB1. However, blockade of the HMGB1-TLR4 axis retards seizure onset also in the bicuculline-induced nonlesional model of seizures, suggesting that neuronal overexcitation itself is sufficient to promote HMGB1 release and that cell death is not a prerequisite. In addition to the release of preformed HMGB1 at seizure onset, new synthesis of HMGB1 occurs in the hippocampus after seizure precipitation, as shown by immunohistochemistry and western blotting. Concomitantly with new synthesis of HMGB1, we observe HMGB1 in the cytoplasm of astrocytes and microglia, suggesting that glial cells actively secrete HMGB1, although this is difficult to show in vivo. TLR4 expression after seizure precipitation is also increased from basal conditions in normal brain tissue. Although TLR4 protein is not detectable by immunohistochemistry in control tissue, TLR4 transcript is present 18 , indicating a readily available machinery for protein upregulation.
The cause of HMGB1 relocation and synthesis in glia, and of TLR4 expression during seizures, remains unknown. We could not induce HMGB1 synthesis or secretion by rat microglia and astrocytes after incubation with kainic acid, glutamate or inflammatory mediators such as tumor necrosis factor-α, IL-1β, ATP or a combination of all three (data not shown). Hypoxia has been shown in several scenarios to cause HMGB1 relocation, synthesis or both 36, 48, 49 ; however, only a temporary mild decrease in tissue oxygenation occurs in the epileptic focus in the early phase of ictal activity 50 . Moreover, hypoxia has been shown to induce transcriptional downregulation of TLR4 in cell cultures 51 .
In any event, increased HMGB1 expression and secretion by glial cells during seizures is expected to support a second and sustained wave of extracellular HMGB1, distinct from the first wave from overexcited neurons at seizure onset. Both waves possibly enforce an autocrine and paracrine loop supporting neuronal hyperexcitability and sustain inflammation via nuclear factor-κB-and/or activator protein-1-dependent transcription of inflammatory genes, including IL-1β. TLR4 induction in neurons and astrocytes can further support the efficacy and duration of this autocrine or paracrine loop.
The presence of cytoplasmic HMGB1 in a high percentage of glial cells and high TLR4 expression in brain specimens from subjects with TLE, who are highly prone to seizure precipitation, suggests that these molecules might have key roles in human epilepsy. Widespectrum anti-inflammatory drugs, such as steroids, are effective in some types of epilepsy 3 . However, HMGB1 and TLR4 may be optimal targets for antiepileptic treatments; indeed, HMGB1 and TLR4 inhibitors are active in the mouse model of chronic seizures, which is resistant to a range of anticonvulsant drugs 29 . Pharmacological interventions targeting HMGB1 are already under development for several disorders 52 and may prove effective for epilepsies that are currently drug resistant.
